Drug Profile
XRx 221
Alternative Names: Xrx-221; XRx221Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator XORTX Pharma
- Developer XORTX Therapeutics
- Class Uroprotectives
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetic nephropathies
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Diabetic-nephropathies in Canada
- 06 Apr 2021 XORTX Pharma has patent protection for the use of uric acid lowering agents to treat chronic progressing kidney disease, hypertension, insulin resistance, and diabetic nephropathy, in USA and Europe Union
- 06 Apr 2021 XORTX Pharma receives notification of intent to grant a patent covering the use of uric acid lowering agents to treat and prevent diabetic nephropathies, in European Union